nvax
April 27th, 2009
Novavax, Inc. (NVAX) is another clinical stage company using its virus-like particle platform technology for flu treatments; stock is indicated north of $2.50 after closing up some 75% at $1.42 Friday. NVAX for instance had a huge move (75%) higher on Friday on a hugh increase in volume. This stock was also in play for the Asian Bird Flu scare a few years ago. This will almost certainly get a gap higher on Monday, so at this point, NVAX and BCRX are up the most in the pre and will likely POP the most due to the most following. SVA tends to lag the move – its China based, not sure if that matters, but if China market drags it effects its performance.